September 1, 2024

Bedrocan Spotlights Syqe’s Clinical Research on Gender Differences in Medical Cannabis Inhalation

An article by Bedrocan about Syqe®’s study showed that women and men who suffer from chronic neuropathic pain respond to medical cannabis in a similar when administered through the SyqeAir Inhaler.

Israeli Medical Cannabis Inhaler Gets Canada’s Marketing Nod

28/04/2021

Approval is the first by an international regulator allowing the marketing of a precisely dosed cannabis inhaler as a medical product, Syqe® Medical says.

Israeli Microdosing Cannabis Inhaler Receives Approval In Canada

29/04/2021

The real-world data of the trials showed that patients experienced a 90% reduction in adverse effects associated with marijuana use in comparison with other methods such as oil, smoking, and vaping.

Study Finds Medical Cannabis Reduces Cancer Patients’ Pain And Need For Opiates

25/05/2022

Researchers in Israel found that the use of medical cannabis reduced cancer patients’ pain and use of painkillers in a recently published study.

Medical Cannabis

SyqeAir Inhaler

Useful Information

Media

Contact Syqe®

Phone. +972-3-376-7338
Email. info@syqemed.com
Syqe® Israel. syqe.co.il

Show Us Some Love

The site and the content therein are provided for general knowledge only and do not constitute advertising and/or medical, pharmacological, or professional advice, diagnosis, treatment, or other healthcare services that in any way generate a doctor-patient relationship and/or recommendation for treatment or products in general, and for medical cannabis products and/or SyqeAir inhaler in particular. You should make all medical or health-related decisions on the basis of professional advice from a licensed physician or qualified healthcare professional who is fully aware of your individual circumstances. For any questions regarding products, including medical cannabis products and/or the SyqeAir inhaler, please consult your attending physician and/or the pharmacist at the dispensing pharmacy. The use and reliance on all content appearing on this site are at your sole responsibility, and Syqe® will not be responsible for any decision or action taken by you as a result of relying on this site.

Day: September 1, 2024

Bedrocan Spotlights Syqe’s Clinical Research on Gender Differences in Medical Cannabis Inhalation

Related Posts

Israeli Medical Cannabis Inhaler Gets Canada’s Marketing Nod

Israeli Microdosing Cannabis Inhaler Receives Approval In Canada

Study Finds Medical Cannabis Reduces Cancer Patients’ Pain And Need For Opiates